The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females
Aims To assess whether treatment with statins or renin-angiotensin-aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and e...
Gespeichert in:
| Veröffentlicht in: | Europace (London, England) England), 2010-03, Vol.12 (3), p.322-330 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 330 |
|---|---|
| container_issue | 3 |
| container_start_page | 322 |
| container_title | Europace (London, England) |
| container_volume | 12 |
| creator | Patel, Dimpi Mohanty, Prasant Di Biase, Luigi Wang, Yan Shaheen, Mazen H. Sanchez, Javier E. Horton, Rodney P. Gallinghouse, G. Joseph Zagrodzky, Jason D. Bailey, Shane M. Burkhardt, J. David Lewis, William R. Diaz, Alberto Beheiry, Salwa Hongo, Richard Al-Ahmad, Amin Wang, Paul Schweikert, Robert Natale, Andrea |
| description | Aims
To assess whether treatment with statins or renin-angiotensin-aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS).
Methods and results
Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8%) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2%) patients in the study. Out of 372 patients, 111 (29.8%) were on statins (Group 1), 59 (15.9%) on RAAS inhibitors (Group 2), and 202 (54.3%) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6%) in Group 1, 38 (65.4%) in Group 2, and 139 (68.8%) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively).
Conclusion
Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time. |
| doi_str_mv | 10.1093/europace/eup387 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_TOX</sourceid><recordid>TN_cdi_proquest_miscellaneous_733954231</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/europace/eup387</oup_id><sourcerecordid>733954231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-3101e2b77e81374da76ba68afeac6a8edf70cbe78d95e050168df21532ad1b203</originalsourceid><addsrcrecordid>eNqFkctKxDAUhoMojre1O8lOEKq5TJt2KeINBDe6Lml7qtVcak4i-BI-sxlmdOsqP5wvH8n5CTnm7JyzRl5ACn7WPeQwy1ptkT1eSlEI1ojtnFnTFCUXzYLsI74xxpRoyl2yEIxVy1qIPfL99Ap0stkRqR8pRh0nh1S7gQZwkyu0e5l8BIerbAaPEYJ3QPErJ0s74_t3CEi9o3My1jsdvugnTC47YkiWTuhNlua5T7H3FpDm4ZxFhQWXX59QGzqC1QbwkOyM2iAcbc4D8nxz_XR1Vzw83t5fXT4U_VLWsZCccRCdUlBzqZaDVlWnq1qPoPtK1zCMivUdqHpoSmAl41U9jGK1Gj3wTjB5QE7X3jn4jwQYWzthD8ZoBz5hq6RsyqWQPJMXa7IPHjHA2M5hsvmTLWftqoP2t4N23UG-cbJxp87C8Mf_Lj0DZ2vAp_lf2w8dF5j4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733954231</pqid></control><display><type>article</type><title>The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females</title><source>Oxford Journals Open Access Collection</source><creator>Patel, Dimpi ; Mohanty, Prasant ; Di Biase, Luigi ; Wang, Yan ; Shaheen, Mazen H. ; Sanchez, Javier E. ; Horton, Rodney P. ; Gallinghouse, G. Joseph ; Zagrodzky, Jason D. ; Bailey, Shane M. ; Burkhardt, J. David ; Lewis, William R. ; Diaz, Alberto ; Beheiry, Salwa ; Hongo, Richard ; Al-Ahmad, Amin ; Wang, Paul ; Schweikert, Robert ; Natale, Andrea</creator><creatorcontrib>Patel, Dimpi ; Mohanty, Prasant ; Di Biase, Luigi ; Wang, Yan ; Shaheen, Mazen H. ; Sanchez, Javier E. ; Horton, Rodney P. ; Gallinghouse, G. Joseph ; Zagrodzky, Jason D. ; Bailey, Shane M. ; Burkhardt, J. David ; Lewis, William R. ; Diaz, Alberto ; Beheiry, Salwa ; Hongo, Richard ; Al-Ahmad, Amin ; Wang, Paul ; Schweikert, Robert ; Natale, Andrea</creatorcontrib><description>Aims
To assess whether treatment with statins or renin-angiotensin-aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS).
Methods and results
Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8%) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2%) patients in the study. Out of 372 patients, 111 (29.8%) were on statins (Group 1), 59 (15.9%) on RAAS inhibitors (Group 2), and 202 (54.3%) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6%) in Group 1, 38 (65.4%) in Group 2, and 139 (68.8%) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively).
Conclusion
Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.</description><identifier>ISSN: 1099-5129</identifier><identifier>EISSN: 1532-2092</identifier><identifier>DOI: 10.1093/europace/eup387</identifier><identifier>PMID: 20064822</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Aged ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - epidemiology ; Atrial Fibrillation - surgery ; C-Reactive Protein - metabolism ; Catheter Ablation - methods ; Catheter Ablation - statistics & numerical data ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Kaplan-Meier Estimate ; Middle Aged ; Postmenopause ; Postoperative Complications - epidemiology ; Postoperative Complications - prevention & control ; Predictive Value of Tests ; Proportional Hazards Models ; Renin-Angiotensin System - drug effects ; Risk Factors ; Secondary Prevention ; Treatment Outcome</subject><ispartof>Europace (London, England), 2010-03, Vol.12 (3), p.322-330</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org. 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-3101e2b77e81374da76ba68afeac6a8edf70cbe78d95e050168df21532ad1b203</citedby><cites>FETCH-LOGICAL-c438t-3101e2b77e81374da76ba68afeac6a8edf70cbe78d95e050168df21532ad1b203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1598,27901,27902</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/europace/eup387$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20064822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patel, Dimpi</creatorcontrib><creatorcontrib>Mohanty, Prasant</creatorcontrib><creatorcontrib>Di Biase, Luigi</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Shaheen, Mazen H.</creatorcontrib><creatorcontrib>Sanchez, Javier E.</creatorcontrib><creatorcontrib>Horton, Rodney P.</creatorcontrib><creatorcontrib>Gallinghouse, G. Joseph</creatorcontrib><creatorcontrib>Zagrodzky, Jason D.</creatorcontrib><creatorcontrib>Bailey, Shane M.</creatorcontrib><creatorcontrib>Burkhardt, J. David</creatorcontrib><creatorcontrib>Lewis, William R.</creatorcontrib><creatorcontrib>Diaz, Alberto</creatorcontrib><creatorcontrib>Beheiry, Salwa</creatorcontrib><creatorcontrib>Hongo, Richard</creatorcontrib><creatorcontrib>Al-Ahmad, Amin</creatorcontrib><creatorcontrib>Wang, Paul</creatorcontrib><creatorcontrib>Schweikert, Robert</creatorcontrib><creatorcontrib>Natale, Andrea</creatorcontrib><title>The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females</title><title>Europace (London, England)</title><addtitle>Europace</addtitle><description>Aims
To assess whether treatment with statins or renin-angiotensin-aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS).
Methods and results
Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8%) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2%) patients in the study. Out of 372 patients, 111 (29.8%) were on statins (Group 1), 59 (15.9%) on RAAS inhibitors (Group 2), and 202 (54.3%) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6%) in Group 1, 38 (65.4%) in Group 2, and 139 (68.8%) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively).
Conclusion
Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.</description><subject>Aged</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - epidemiology</subject><subject>Atrial Fibrillation - surgery</subject><subject>C-Reactive Protein - metabolism</subject><subject>Catheter Ablation - methods</subject><subject>Catheter Ablation - statistics & numerical data</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Kaplan-Meier Estimate</subject><subject>Middle Aged</subject><subject>Postmenopause</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Complications - prevention & control</subject><subject>Predictive Value of Tests</subject><subject>Proportional Hazards Models</subject><subject>Renin-Angiotensin System - drug effects</subject><subject>Risk Factors</subject><subject>Secondary Prevention</subject><subject>Treatment Outcome</subject><issn>1099-5129</issn><issn>1532-2092</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctKxDAUhoMojre1O8lOEKq5TJt2KeINBDe6Lml7qtVcak4i-BI-sxlmdOsqP5wvH8n5CTnm7JyzRl5ACn7WPeQwy1ptkT1eSlEI1ojtnFnTFCUXzYLsI74xxpRoyl2yEIxVy1qIPfL99Ap0stkRqR8pRh0nh1S7gQZwkyu0e5l8BIerbAaPEYJ3QPErJ0s74_t3CEi9o3My1jsdvugnTC47YkiWTuhNlua5T7H3FpDm4ZxFhQWXX59QGzqC1QbwkOyM2iAcbc4D8nxz_XR1Vzw83t5fXT4U_VLWsZCccRCdUlBzqZaDVlWnq1qPoPtK1zCMivUdqHpoSmAl41U9jGK1Gj3wTjB5QE7X3jn4jwQYWzthD8ZoBz5hq6RsyqWQPJMXa7IPHjHA2M5hsvmTLWftqoP2t4N23UG-cbJxp87C8Mf_Lj0DZ2vAp_lf2w8dF5j4</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Patel, Dimpi</creator><creator>Mohanty, Prasant</creator><creator>Di Biase, Luigi</creator><creator>Wang, Yan</creator><creator>Shaheen, Mazen H.</creator><creator>Sanchez, Javier E.</creator><creator>Horton, Rodney P.</creator><creator>Gallinghouse, G. Joseph</creator><creator>Zagrodzky, Jason D.</creator><creator>Bailey, Shane M.</creator><creator>Burkhardt, J. David</creator><creator>Lewis, William R.</creator><creator>Diaz, Alberto</creator><creator>Beheiry, Salwa</creator><creator>Hongo, Richard</creator><creator>Al-Ahmad, Amin</creator><creator>Wang, Paul</creator><creator>Schweikert, Robert</creator><creator>Natale, Andrea</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females</title><author>Patel, Dimpi ; Mohanty, Prasant ; Di Biase, Luigi ; Wang, Yan ; Shaheen, Mazen H. ; Sanchez, Javier E. ; Horton, Rodney P. ; Gallinghouse, G. Joseph ; Zagrodzky, Jason D. ; Bailey, Shane M. ; Burkhardt, J. David ; Lewis, William R. ; Diaz, Alberto ; Beheiry, Salwa ; Hongo, Richard ; Al-Ahmad, Amin ; Wang, Paul ; Schweikert, Robert ; Natale, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-3101e2b77e81374da76ba68afeac6a8edf70cbe78d95e050168df21532ad1b203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - epidemiology</topic><topic>Atrial Fibrillation - surgery</topic><topic>C-Reactive Protein - metabolism</topic><topic>Catheter Ablation - methods</topic><topic>Catheter Ablation - statistics & numerical data</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Kaplan-Meier Estimate</topic><topic>Middle Aged</topic><topic>Postmenopause</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Complications - prevention & control</topic><topic>Predictive Value of Tests</topic><topic>Proportional Hazards Models</topic><topic>Renin-Angiotensin System - drug effects</topic><topic>Risk Factors</topic><topic>Secondary Prevention</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patel, Dimpi</creatorcontrib><creatorcontrib>Mohanty, Prasant</creatorcontrib><creatorcontrib>Di Biase, Luigi</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Shaheen, Mazen H.</creatorcontrib><creatorcontrib>Sanchez, Javier E.</creatorcontrib><creatorcontrib>Horton, Rodney P.</creatorcontrib><creatorcontrib>Gallinghouse, G. Joseph</creatorcontrib><creatorcontrib>Zagrodzky, Jason D.</creatorcontrib><creatorcontrib>Bailey, Shane M.</creatorcontrib><creatorcontrib>Burkhardt, J. David</creatorcontrib><creatorcontrib>Lewis, William R.</creatorcontrib><creatorcontrib>Diaz, Alberto</creatorcontrib><creatorcontrib>Beheiry, Salwa</creatorcontrib><creatorcontrib>Hongo, Richard</creatorcontrib><creatorcontrib>Al-Ahmad, Amin</creatorcontrib><creatorcontrib>Wang, Paul</creatorcontrib><creatorcontrib>Schweikert, Robert</creatorcontrib><creatorcontrib>Natale, Andrea</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Europace (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Patel, Dimpi</au><au>Mohanty, Prasant</au><au>Di Biase, Luigi</au><au>Wang, Yan</au><au>Shaheen, Mazen H.</au><au>Sanchez, Javier E.</au><au>Horton, Rodney P.</au><au>Gallinghouse, G. Joseph</au><au>Zagrodzky, Jason D.</au><au>Bailey, Shane M.</au><au>Burkhardt, J. David</au><au>Lewis, William R.</au><au>Diaz, Alberto</au><au>Beheiry, Salwa</au><au>Hongo, Richard</au><au>Al-Ahmad, Amin</au><au>Wang, Paul</au><au>Schweikert, Robert</au><au>Natale, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females</atitle><jtitle>Europace (London, England)</jtitle><addtitle>Europace</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>12</volume><issue>3</issue><spage>322</spage><epage>330</epage><pages>322-330</pages><issn>1099-5129</issn><eissn>1532-2092</eissn><abstract>Aims
To assess whether treatment with statins or renin-angiotensin-aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS).
Methods and results
Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8%) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2%) patients in the study. Out of 372 patients, 111 (29.8%) were on statins (Group 1), 59 (15.9%) on RAAS inhibitors (Group 2), and 202 (54.3%) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6%) in Group 1, 38 (65.4%) in Group 2, and 139 (68.8%) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively).
Conclusion
Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>20064822</pmid><doi>10.1093/europace/eup387</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1099-5129 |
| ispartof | Europace (London, England), 2010-03, Vol.12 (3), p.322-330 |
| issn | 1099-5129 1532-2092 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733954231 |
| source | Oxford Journals Open Access Collection |
| subjects | Aged Angiotensin II Type 1 Receptor Blockers - therapeutic use Atrial Fibrillation - drug therapy Atrial Fibrillation - epidemiology Atrial Fibrillation - surgery C-Reactive Protein - metabolism Catheter Ablation - methods Catheter Ablation - statistics & numerical data Combined Modality Therapy Female Follow-Up Studies Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Kaplan-Meier Estimate Middle Aged Postmenopause Postoperative Complications - epidemiology Postoperative Complications - prevention & control Predictive Value of Tests Proportional Hazards Models Renin-Angiotensin System - drug effects Risk Factors Secondary Prevention Treatment Outcome |
| title | The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T04%3A13%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20statins%20and%20renin-angiotensin-aldosterone%20system%20blockers%20on%20pulmonary%20vein%20antrum%20isolation%20outcomes%20in%20post-menopausal%20females&rft.jtitle=Europace%20(London,%20England)&rft.au=Patel,%20Dimpi&rft.date=2010-03-01&rft.volume=12&rft.issue=3&rft.spage=322&rft.epage=330&rft.pages=322-330&rft.issn=1099-5129&rft.eissn=1532-2092&rft_id=info:doi/10.1093/europace/eup387&rft_dat=%3Cproquest_TOX%3E733954231%3C/proquest_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733954231&rft_id=info:pmid/20064822&rft_oup_id=10.1093/europace/eup387&rfr_iscdi=true |